Prevalence of germline pathogenic variants in cancer predisposition genes in the Japanese population
Japanese Journal of Clinical Oncology · 2026
DOI: 10.1093/jjco/hyaf181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Tatsuro Yamaguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Germ-Line Mutation, Genetic Predisposition to Disease, Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit nennt 33 Literaturangaben. Gefördert von: JSPS, Office of Metropolitan Hospital Management of the Tokyo Metropolitan Government.
Abstract (Originalsprache)
Background
Germline pathogenic variants (GPVs) in cancer predisposition genes increase cancer risk, but their population-level prevalence in Japan remains unclear.
Aim
To estimate the prevalence of GPV carriers of hereditary cancer predisposition syndromes (HCPSs) in the Japanese population. Data source and methods A cross-sectional analysis of the Tohoku Medical Megabank Organization datasets was conducted to assess allele frequencies of rare GPVs, estimate carrier prevalence, and describe variant distribution.
Results
The cumulative allele frequency of rare GPVs of cancer predisposing genes was 1.47% for autosomal dominant and 3.20% for autosomal recessive diseases. The estimated prevalence of GPV carriers was 2.90% (1 in 35 individuals) and 0.10% (1 in 977 individuals) for autosomal dominant HCPSs and autosomal recessive HCPSs, respectively; ~6.19% of the population (1 in 16 individuals) were carriers. Variant types differed across genes, and hotspot variants had a significant impact on allele frequencies. Moreover, 47 structural variants (0.28%) having the potential to cause structural disruption were identified.
Conclusions
Allele frequency analysis of rare GPVs of cancer predisposition genes offered valuable insight into the prevalence of GPV carriers of HCPSs in the Japanese population. Hotspot variants may represent founder mutations within specific ethnic groups, and their presence or absence could affect gene-specific allele frequencies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Department of Clinical Genetics, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
- Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
- Department of Clinical Genetics, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
ORCID-Profile: Tatsuro Yamaguchi, Kazushige Kawai, Takeshi Yamada
Förderung
- JSPS
- Office of Metropolitan Hospital Management of the Tokyo Metropolitan Government
Zitieren
APA
Yamaguchi, T., Kawai, K., Takao, M., Takao, A., Mori, Y., Arai, M., Kumamoto, K., Yamada, T., & Ishida, H. (2026). Prevalence of germline pathogenic variants in cancer predisposition genes in the Japanese population. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf181
Vancouver
Yamaguchi T, Kawai K, Takao M, Takao A, Mori Y, Arai M, et al. Prevalence of germline pathogenic variants in cancer predisposition genes in the Japanese population. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf181
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Tatsuro and Kawai, Kazushige and Takao, Misato and Takao, Akinari and Mori, Yoshiko and Arai, Masami and Kumamoto, Kensuke and Yamada, Takeshi and Ishida, Hideyuki},
title = {Prevalence of germline pathogenic variants in cancer predisposition genes in the Japanese population},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
doi = {10.1093/jjco/hyaf181}
}
EUVIMED